# Erica M Wood

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1209963/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 183 papers | 6,138 citations | 81743 39 h-index | 85405 71 g-index |
| 190 all docs | 190 docs citations | 190 times ranked | 8292 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. New England Journal of Medicine, 2018, 379, 1509-1518. | 13.9 | 770 |
| 2 | A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. New England Journal of Medicine, 2013, 368, 1771-1780. | 13.9 | 384 |
| 3 | Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Medical Journal of Australia, 2004, 181, 492-497. | 0.8 | 297 |
| 4 | Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. The Cochrane Library, 2020, 7, CD013600. | 1.5 | 235 |
| 5 | Diagnosis and management of iron deficiency anaemia: a clinical update. Medical Journal of Australia, 2010, 193, 525-532. | 0.8 | 226 |
| 6 | Effect of Convalescent Plasma on Organ Supportâ€“Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690. | 3.8 | 169 |
| 7 | Serum ferritin as an indicator of iron status: what do we need to know?. American Journal of Clinical Nutrition, 2017, 106, 1634S-1639S. | 2.2 | 150 |
| 8 | An update of consensus guidelines for warfarin reversal. Medical Journal of Australia, 2013, 198, 198-199. | 0.8 | 135 |
| 9 | Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. The Cochrane Library, 2020, 5, CD013600. | 1.5 | 133 |
| 10 | SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. The Cochrane Library, 2021, 2021, CD013825. | 1.5 | 114 |
| 11 | Fibrinogen is an independent predictor of mortality in major trauma patients: A five-year statewide cohort study. Injury, 2017, 48, 1074-1081. | 0.7 | 109 |
| 12 | Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. The Cochrane Library, 2021, 2021, CD013600. | 1.5 | 109 |
| 13 | Managing haematology and oncology patients during the <scp>COVID</scp> â€19 pandemic: interim consensus guidance. Medical Journal of Australia, 2020, 212, 481-489. | 0.8 | 107 |
| 14 | Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. The Cochrane Library, 2020, 10, CD013600. | 1.5 | 91 |
| 15 | Age of red blood cells and mortality in the critically ill. Critical Care, 2011, 15, R116. | 2.5 | 89 |
| 16 | Guidance on Platelet Transfusion for Patients With Hypoproliferative Thrombocytopenia. Transfusion Medicine Reviews, 2015, 29, 3-13. | 0.9 | 87 |
| 17 | Optimal Dose, Timing and Ratio of Blood Products in Massive Transfusion: Results from a Systematic Review. Transfusion Medicine Reviews, 2018, 32, 6-15. | 0.9 | 87 |
| 18 | Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica, 2011, 96, 1099-1105. | 1.7 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Reducing the risk of transfusionâ€transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. Transfusion, 2008, 48, 55-63. | 0.8 | 67 |
| 20 | The International Haemovigilance Network Database for the Surveillance of Adverse Reactions and Events in Donors and Recipients of Blood Components: technical issues and results. Vox Sanguinis, 2016, 111, 409-417. | 0.7 | 67 |
| 21 | Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy and Childbirth, 2013, 13, 96. | 0.9 | 63 |
| 22 | Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica, 2015, 100, 740-747. | 1.7 | 61 |
| 23 | Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of theP. vivaxligand required for blood-stage infection. FEBS Letters, 2001, 495, 111-114. | 1.3 | 60 |
| 24 | It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies. Transfusion, 2019, 59, 3794-3799. | 0.8 | 60 |
| 25 | Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion. Vox Sanguinis, 2014, 107, 60-70. | 0.7 | 58 |
| 26 | Wrong blood in tube â€“ potential for serious outcomes: can it be prevented?. British Journal of Haematology, 2015, 168, 3-13. | 1.2 | 57 |
| 27 | Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology, 2020, 189, 279-290. | 1.2 | 56 |
| 28 | Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial (CME). Transfusion, 2014, 54, 2385-2393. | 0.8 | 54 |
| 29 | Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut, 2021, 70, 717-724. | 6.1 | 54 |
| 30 | Transfusion Interventions in Critical Bleeding Requiring Massive Transfusion: A Systematic Review. Transfusion Medicine Reviews, 2015, 29, 127-137. | 0.9 | 47 |
| 31 | Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry. Internal Medicine Journal, 2016, 46, 71-79. | 0.5 | 47 |
| 32 | Do All Patients With Hematologic Malignancies and Severe Thrombocytopenia Need Prophylactic Platelet Transfusions?. Transfusion Medicine Reviews, 2010, 24, 163-171. | 0.9 | 46 |
| 33 | The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion, 2013, 53, 1531-1543. | 0.8 | 46 |
| 34 | Neonatal transfusions. Vox Sanguinis, 2009, 96, 62-85. | 0.7 | 45 |
| 35 | Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica, 2017, 102, 2021-2029. | 1.7 | 45 |
| 36 | Establishment of the first International Repository for Transfusionâ€Relevant Bacteria Reference Strains: ISBT Working Party Transfusionâ€Transmitted Infectious Diseases (WPâ€TTID), Subgroup on Bacteria. Vox Sanguinis, 2012, 102, 22-31. | 0.7 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Transfusion practice varies widely in cardiac surgery: Results from aÂnational registry. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1684-1690.e1. | 0.4 | 43 |
| 38 | Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use. Transfusion, 2009, 49, 2296-2303. | 0.8 | 42 |
| 39 | Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a populationâ€based data linkage study. Cancer, 2014, 120, 1686-1694. | 2.0 | 41 |
| 40 | Detection of bacterial contamination of platelet concentrates. Vox Sanguinis, 2007, 93, 260-277. | 0.7 | 40 |
| 41 | International haemovigilance: what have we learned and what do we need to do next?. Transfusion Medicine, 2019, 29, 221-230. | 0.5 | 40 |
| 42 | Fibrinogen concentration and use of fibrinogen supplementation with cryoprecipitate in patients with critical bleeding receiving massive transfusion: a biâ€national cohort study. British Journal of Haematology, 2017, 179, 131-141. | 1.2 | 39 |
| 43 | A review of pathophysiology and current treatment for neonatal alloimmune thrombocytopenia (NAIT) and introducing the Australian NAIT registry. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2011, 51, 191-198. | 0.4 | 36 |
| 44 | Descriptive characteristics and inâ€hospital mortality of critically bleeding patients requiring massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry. Vox Sanguinis, 2017, 112, 240-248. | 0.7 | 36 |
| 45 | A â€˜Dangerousâ€™ Group O Donor: Severe Hemolysis in All Recipients of Organs from a Donor with Multiple Red Cell Alloantibodies. American Journal of Transplantation, 2008, 8, 711-714. | 2.6 | 35 |
| 46 | Reduction of body iron in HFE -related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. Lancet Haematology,the, 2017, 4, e607-e614. | 2.2 | 35 |
| 47 | Myeloma in the Real World: What Is Really Happening?. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 133-144.e1. | 0.2 | 34 |
| 48 | Transfusing blood safely and appropriately. BMJ, The, 2013, 347, f4303-f4303. | 3.0 | 33 |
| 49 | Maternal <scp>HPA</scp>â€1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. Vox Sanguinis, 2019, 114, 79-94. | 0.7 | 33 |
| 50 | Clinical use of Convalescent Plasma in the COVIDâ€19 pandemic: a transfusionâ€focussed gap analysis with recommendations for future research priorities. Vox Sanguinis, 2021, 116, 88-98. | 0.7 | 30 |
| 51 | How should we use convalescent plasma therapies for the management of COVID-19?. Blood, 2021, 137, 1573-1581. | 0.6 | 29 |
| 52 | Hemoglobin and iron indices in nonanemic premenopausal blood donors predict future deferral from whole blood donation. Transfusion, 2011, 51, 2709-2713. | 0.8 | 28 |
| 53 | Accuracy of predonation Hct sampling affects donor safety, eligibility, and deferral rates. Transfusion, 2001, 41, 353-359. | 0.8 | 27 |
| 54 | Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Annals of Hematology, 2011, 90, 1167-1172. | 0.8 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk. Transfusion Medicine Reviews, 2017, 31, 154-164. | 0.9 | 27 |
| 56 | Education in transfusion medicine for medical students and doctors. Vox Sanguinis, 2013, 104, 250-272. | 0.7 | 26 |
| 57 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. The Cochrane Library, 2020, 2020, CD010981. | 1.5 | 26 |
| 58 | Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Internal Medicine Journal, 2018, 48, 624-636. | 0.5 | 26 |
| 59 | The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial. Blood, 2012, 120, 1-1. | 0.6 | 26 |
| 60 | Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. BMC Medical Research Methodology, 2016, 16, 151. | 1.4 | 25 |
| 61 | Quality of Evidence-Based Guidelines for Transfusion of Red Blood Cells and Plasma: A Systematic Review. Transfusion Medicine Reviews, 2018, 32, 135-143. | 0.9 | 25 |
| 62 | Bacterial safety of cellâ€based therapeutic preparations, focusing on haematopoietic progenitor cells. Vox Sanguinis, 2014, 106, 285-296. | 0.7 | 24 |
| 63 | Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. Vaccine, 2021, 39, 7052-7057. | 1.7 | 24 |
| 64 | Pathogen inactivation of platelet concentrates. Vox Sanguinis, 2010, 99, 85-95. | 0.7 | 23 |
| 65 | Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an ‹scp›A‹/scp›ustralian populationâ€based study 1998 to 2008. Transfusion, 2013, 53, 1714-1721. | 0.8 | 23 |
| 66 | Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes. Cancer, 2015, 121, 2892-2899. | 2.0 | 22 |
| 67 | Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study. Transfusion, 2016, 56, 2455-2465. | 0.8 | 22 |
| 68 | False positive viral marker results in blood donors and their unintended consequences. Vox Sanguinis, 2018, 113, 530-539. | 0.7 | 22 |
| 69 | Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology, 2018, 23, 507-517. | 0.7 | 21 |
| 70 | Outpatient transfusions for myelodysplastic syndromes. Hematology American Society of Hematology Education Program, 2020, 2020, 167-174. | 0.9 | 21 |
| 71 | Intravenous immunoglobulin in critically ill adults: When and what is the evidence?. Journal of Critical Care, 2015, 30, 652.e9-652.e16. | 1.0 | 20 |
| 72 | The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial. Trials, 2019, 20, 592. | 0.7 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. The Cochrane Library, 2022, 2022, . | 1.5 | 20 |
| 74 | Clinical transfusion practice update: haemovigilance, complications, patient blood management and national standards. Medical Journal of Australia, 2013, 199, 397-401. | 0.8 | 19 |
| 75 | Can We Improve the Management of Blood Donors With Nonspecific Reactivity in Viral Screening and Confirmatory Assays?. Transfusion Medicine Reviews, 2005, 19, 58-65. | 0.9 | 18 |
| 76 | Bacterial Pre-Release Testing of Platelets â€“ the Australian Red Cross Blood Service Clinical Experience. Transfusion Medicine and Hemotherapy, 2011, 38, 239-241. | 0.7 | 18 |
| 77 | The Evolving Role of the Transfusion Practitioner. Transfusion Medicine Reviews, 2015, 29, 138-144. | 0.9 | 18 |
| 78 | Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. Internal Medicine Journal, 2017, 47, 695-698. | 0.5 | 18 |
| 79 | Subgroup analysis of the ASPirin in Reducing Events in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. Kidney International, 2021, 99, 466-474. | 2.6 | 18 |
| 80 | Epidemiology of Massive Transfusion â€“ A Common Intervention in Need of a Definition. Transfusion Medicine Reviews, 2021, 35, 73-79. | 0.9 | 18 |
| 81 | <scp>N</scp>â€Acetylcysteine for thrombotic thrombocytopenic purpura: is a von <scp>W</scp>illebrand factorâ€“inhibitory dose feasible in vivo?. Transfusion, 2014, 54, 2362-2363. | 0.8 | 17 |
| 82 | An international investigation into O red blood cell unit administration in hospitals: the GRoup O Utilization Patterns (GROUP) study. Transfusion, 2017, 57, 2329-2337. | 0.8 | 17 |
| 83 | Massive transfusions for critical bleeding: is everything old new again?. Transfusion Medicine, 2018, 28, 140-149. | 0.5 | 17 |
| 84 | International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the <scp>COVID</scp>â€19 pandemic. Vox Sanguinis, 2022, 117, 822-830. | 0.7 | 17 |
| 85 | Hospital blood bank information systems accurately reflect patient transfusion: results of a validation study. Transfusion, 2011, 51, 943-948. | 0.8 | 16 |
| 86 | Bronchial thermoplasty in severe asthma in Australia. Internal Medicine Journal, 2017, 47, 536-541. | 0.5 | 16 |
| 87 | Is Platelet Expiring Out of Date? A Systematic Review. Transfusion Medicine Reviews, 2020, 34, 42-50. | 0.9 | 16 |
| 88 | Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. Internal Medicine Journal, 2019, 49, 152-159. | 0.5 | 15 |
| 89 | A review on decision support for massive transfusion: understanding human factors to support the implementation of complex interventions in trauma. Transfusion, 2012, 52, 2692-2705. | 0.8 | 14 |
| 90 | Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Contemporary Clinical Trials Communications, 2018, 11, 30-36. | 0.5 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Approaches to understanding and interpreting the risks of red blood cell transfusion in neonates. Transfusion Medicine, 2019, 29, 231-238. | 0.5 | 13 |
| 92 | Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e415-e424. | 0.2 | 13 |
| 93 | Expression of Duffy antigen receptor for chemokines during reticulocyte maturation: using a CD71 flow cytometric technique to identify reticulocytes. Immunohematology, 2005, 21, 15-20. | 0.2 | 13 |
| 94 | Blood transfusion requirements for patients undergoing chemotherapy for acute myeloid leukemia how much is enough?. Haematologica, 2007, 92, 996-997. | 1.7 | 12 |
| 95 | Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron). BMJ Open, 2015, 5, e008938. | 0.8 | 12 |
| 96 | Introduction of universal prestorage leukodepletion of blood components, and outcomes in transfused cardiac surgery patients. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 216-222. | 0.4 | 12 |
| 97 | Haemoglobin disorders in Australia: where are we now and where will we be in the future?. Internal Medicine Journal, 2016, 46, 770-779. | 0.5 | 12 |
| 98 | The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e510-e520. | 0.2 | 12 |
| 99 | Prevention of monocyte adhesion and inflammatory cytokine production during blood platelet storage: Anin vitro model with implications for transfusion practice. , 2000, 51, 147-154. | | 11 |
| 100 | Logistics of platelet concentrateses. Vox Sanguinis, 2007, 92, 160-181. | 0.7 | 11 |
| 101 | Prophylactic platelet transfusions. Vox Sanguinis, 2012, 103, 159-176. | 0.7 | 11 |
| 102 | Anemia and iron-restricted erythropoiesis in traumatic critical illness. Journal of Trauma and Acute Care Surgery, 2016, 80, 538-545. | 1.1 | 11 |
| 103 | Contemporary management of neonatal alloimmune thrombocytopenia: good outcomes in the intravenous immunoglobulin era: results from the Australian neonatal alloimmune thrombocytopenia registry. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 2488-2494. | 0.7 | 11 |
| 104 | The cost of blood: a study of the total cost of red blood cell transfusion in patients with Î²â€thalassemia using timeâ€driven activityâ€based costing. Transfusion, 2019, 59, 3386-3395. | 0.8 | 11 |
| 105 | The burden of immuneâ€mediated refractoriness to platelet transfusions in myelodysplastic syndromes. Transfusion, 2020, 60, 2192-2198. | 0.8 | 11 |
| 106 | Haematological features, transfusion management and outcomes of massive obstetric haemorrhage: findings from the Australian and New Zealand Massive Transfusion Registry. British Journal of Haematology, 2020, 190, 618-628. | 1.2 | 11 |
| 107 | Methicillin-resistant Staphylococcus aureus sepsis associated with the transfusion of contaminated platelets: a case report. Transfusion, 2001, 41, 1426-1430. | 0.8 | 10 |
| 108 | Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion, 2014, 54, 2394-2403. | 0.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Expression of Duffy antigen receptor for chemokines during reticulocyte maturation: using a CD71 flow cytometric technique to identify reticulocytes. Immunohematology, 2005, 21, 15-20. | 0.2 | 10 |
| 110 | Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey. Internal Medicine Journal, 2019, 49, 358-363. | 0.5 | 9 |
| 111 | A timeâ€driven, activityâ€based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major. Transfusion Medicine, 2019, 29, 33-40. | 0.5 | 9 |
| 112 | Improving outcomes for hospital patients with critical bleeding requiring massive transfusion: the Australian and New Zealand Massive Transfusion Registry study methodology. BMC Research Notes, 2016, 9, 457. | 0.6 | 8 |
| 113 | Heterogeneous hemoglobin lower thresholds in clinical laboratories. American Journal of Hematology, 2018, 93, E142-E144. | 2.0 | 8 |
| 114 | Audit of a paediatric directed donation programme. Journal of Paediatrics and Child Health, 2003, 39, 364-367. | 0.4 | 7 |
| 115 | Preoperative identification of cardiac surgery patients at risk of receiving a platelet transfusion: The Australian Cardiac Surgery Platelet Transfusion ( ACSePT ) risk prediction tool. Transfusion, 2020, 60, 2272-2283. | 0.8 | 7 |
| 116 | Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 2021, 56, 2533-2543. | 1.3 | 7 |
| 117 | Prediction of disability-free survival in healthy older people. GeroScience, 2022, 44, 1641-1655. | 2.1 | 7 |
| 118 | Transfusion service management of sickleâ€cell disease patients. Vox Sanguinis, 2016, 110, 288-294. | 0.7 | 6 |
| 119 | Patientâ€reported outcome measures in multiple myeloma: Realâ€time reporting to improve care (<scp>Myâ€PROMPT</scp>) â€a pilot randomized controlled trial. American Journal of Hematology, 2020, 95, E178-E181. | 2.0 | 6 |
| 120 | Risk Factors for Bleeding: A Modelling Analysis of the TOPPS Randomized Controlled Trial of Prophylactic Platelet Transfusion. Blood, 2014, 124, 1551-1551. | 0.6 | 6 |
| 121 | Hyperhaemolysis in sickle cell disease â€" an unusual and potentially lifeâ€threatening complication. Medical Journal of Australia, 2010, 192, 281-282. | 0.8 | 6 |
| 122 | How well does your massive transfusion protocol perform? A scoping review of quality indicators. Blood Transfusion, 2020, 18, 423-433. | 0.3 | 6 |
| 123 | Platelet Transfusions inÂPatients with Hypoproliferative Thrombocytopenia. Hematology/Oncology Clinics of North America, 2016, 30, 541-560. | 0.9 | 5 |
| 124 | Evaluation of clinical coding data to determine causes of critical bleeding in patients receiving massive transfusion: a biâ€national, multicentre, crossâ€sectional study. Transfusion Medicine, 2017, 27, 114-121. | 0.5 | 5 |
| 125 | Emerging infectious disease agents and blood safety in Australia: spotlight on Zika virus. Medical Journal of Australia, 2017, 206, 455-460. | 0.8 | 5 |
| 126 | Major haemorrhage fatalities in the Australian national coronial database. EMA - Emergency Medicine Australasia, 2018, 30, 382-388. | 0.5 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study. Seminars in Thrombosis and Hemostasis, 2019, 45, 187-195. | 1.5 | 5 |
| 128 | Vox Sanguinis International Forum on Hospital Transfusion Services' Response to COVIDâ€19: Responses. Vox Sanguinis, 2020, 115, e1-e17. | 0.7 | 5 |
| 129 | Epidemiology of Kawasaki disease in Australia using two nationally complete datasets. Journal of Paediatrics and Child Health, 2021, , . | 0.4 | 5 |
| 130 | International Forum on the Management of Major Haemorrhage: Summary. Vox Sanguinis, 2022, 117, 746-753. | 0.7 | 5 |
| 131 | Streptococcus pneumoniae septicemia associated with red blood cell transfusion. Transfusion, 2008, 48, 1520-1521. | 0.8 | 4 |
| 132 | Haemovigilance: concepts and frameworks. ISBT Science Series, 2014, 9, 86-90. | 1.1 | 4 |
| 133 | A dynamic mathematical model of red blood cell clinical demand to assess the impact of prolonged blood shortages and transfusion restriction policies. Transfusion, 2014, 54, 2705-2715. | 0.8 | 4 |
| 134 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. , 2014, , . | | 4 |
| 135 | International survey on definitions and current practices in prevention, diagnosis, management and reporting of transfusionâ€transmitted bacterial infections. ISBT Science Series, 2015, 10, 31-40. | 1.1 | 4 |
| 136 | Diagnostic evaluation and considerations in hypocellular bone marrow failureâ€”A focus on genomics. International Journal of Laboratory Hematology, 2020, 42, 82-89. | 0.7 | 4 |
| 137 | Red cell transfusions: Is less always best?. Transfusion, 2021, 61, 2195-2203. | 0.8 | 4 |
| 138 | Hot and bothered: management and outcomes for patients with febrile nonhemolytic transfusion reactions. Transfusion, 2017, 57, 1639-1641. | 0.8 | 3 |
| 139 | Microbial safety of cellular therapeuticsâ€”lessons from over ten yearsâ€™ experience in microbial safety of platelet concentrates. ISBT Science Series, 2019, 14, 37-44. | 1.1 | 3 |
| 140 | Rationale and design of the intravenous iron for treatment of anemia before cardiac surgery trial. American Heart Journal, 2021, 239, 64-72. | 1.2 | 3 |
| 141 | Monocyte Adhesion to Platelet Concentrate Storage Bags and Cytokine Production. Vox Sanguinis, 2000, 78, 133-133. | 0.7 | 2 |
| 142 | Blood transfusions for iron deficiency anaemia: definitely time for a rethink!. Internal Medicine Journal, 2007, 37, 283-283. | 0.5 | 2 |
| 143 | Critical peptic ulcer bleeding requiring massive blood transfusion: outcomes of 270 cases. Internal Medicine Journal, 2020, , . | 0.5 | 2 |
| 144 | Massive transfusion experience, current practice and decision support: A survey of Australian and New Zealand anaesthetists. Anaesthesia and Intensive Care, 2021, 49, 214-221. | 0.2 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplantâ€ineligible patients with myeloma who are treated with bortezomibâ€based induction. European Journal of Haematology, 2021, 107, 497-499. | 1.1 | 2 |
| 146 | Monosomal Karyotype Is Associated With Worse Survival Independent Of Complex Karyotype In Patients With Myelodysplastic Syndrome. Blood, 2013, 122, 1523-1523. | 0.6 | 2 |
| 147 | The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Blood, 2020, 136, 30-31. | 0.6 | 2 |
| 148 | Home Delivery: Transfusion Services When and Where They Are Needed. Transfusion Medicine Reviews, 2022, 36, 117-124. | 0.9 | 2 |
| 149 | Intravenous immunoglobulin issue policy in NSW: Australian Red Cross Blood Service clarifies â€˜refusal to supplyâ€™. Internal Medicine Journal, 2007, 37, 735-736. | 0.5 | 1 |
| 150 | Duffy antigen expression on reticulocytes does not alter following blood loss in an autologous donation model. Vox Sanguinis, 2009, 97, 268-272. | 0.7 | 1 |
| 151 | An update on indications for platelet transfusion. ISBT Science Series, 2016, 11, 170-176. | 1.1 | 1 |
| 152 | Development of RBC transfusion indications and the collection of patientâ€specific preâ€transfusion information: summary. Vox Sanguinis, 2017, 112, 487-494. | 0.7 | 1 |
| 153 | Red cell transfusion and clinical outcomes in acute pulmonary embolism: Harmful therapy or an indicator of sicker patients with poor prognosis?. Respirology, 2018, 23, 887-888. | 1.3 | 1 |
| 154 | Clinical coding data algorithm to categorize type of gastrointestinal bleeding as a primary reason for massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry. Vox Sanguinis, 2019, 114, 853-860. | 0.7 | 1 |
| 155 | The role of the transfusion practitioner in the management of anaemia. ISBT Science Series, 2020, 15, 82-90. | 1.1 | 1 |
| 156 | Modeling the West Nile virus transfusion transmission risk in a nonoutbreak country associated with traveling donors. Transfusion, 2020, 60, 2611-2621. | 0.8 | 1 |
| 157 | Patient blood management â€“ recommendations from the International Consensus Conference, Frankfurt/Main, Germany. ISBT Science Series, 2021, 16, 226-230. | 1.1 | 1 |
| 158 | International Forum on Transfusion Practices in Haematopoietic Stemâ€Cell Transplantation: Summary. Vox Sanguinis, 2021, 116, 609-612. | 0.7 | 1 |
| 159 | The safety of plasma-derived products in Australia. Australian Prescriber, 2010, 33, 76-79. | 0.5 | 1 |
| 160 | Introduction Of Universal Leucodepletion Associated With a Reduction In New Renal Failure, But Not Infection Or Mortality, In Cardiac Surgery Patients: Results From a Before and After Study. Blood, 2013, 122, 788-788. | 0.6 | 1 |
| 161 | Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 676-683. | 0.6 | 1 |
| 162 | Letter to the Editor. Clinical Immunology, 2001, 98, 383. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | International Forum: 2. Vox Sanguinis, 2003, 85, 226-227. | 0.7 | 0 |
| 164 | The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical research. Internal Medicine Journal, 2009, 39, 72-73. | 0.5 | 0 |
| 165 | Bacterial contamination, screening and follow up: clinical aspects. ISBT Science Series, 2012, 7, 214-219. | 1.1 | 0 |
| 166 | Clinical trials on platelets: recent studies and what next?. ISBT Science Series, 2013, 8, 119-121. | 1.1 | 0 |
| 167 | Transfusion Medicine in Australia. Transfusion Medicine Reviews, 2015, 29, 80-81. | 0.9 | 0 |
| 168 | Development of <scp>RBC</scp> transfusion indications and the collection of patientâ€specific preâ€transfusion information. Vox Sanguinis, 2017, 112, e22-e47. | 0.7 | 0 |
| 169 | Day or overnight transfusion in critically ill patients: does it matter?. Vox Sanguinis, 2018, 113, 275-282. | 0.7 | 0 |
| 170 | Emerging infectious disease agents and blood safety in Australia: spotlight on Zika virus. Medical Journal of Australia, 2018, 208, 96-96. | 0.8 | 0 |
| 171 | Variation in the management of Kawasaki disease in Australia and New Zealand: A survey of paediatricians. Journal of Paediatrics and Child Health, 2021, 57, 646-652. | 0.4 | 0 |
| 172 | What is clinically significant bleeding?. Transfusion, 2021, 61, 340-343. | 0.8 | 0 |
| 173 | International Forum on Transfusion Practices in Haematopoietic Stemâ€Cell Transplantation: Responses. Vox Sanguinis, 2021, 116, e25-e43. | 0.7 | 0 |
| 174 | Age of red blood cells is not associated with in-hospital mortality in massively transfused patients. Journal of Trauma and Acute Care Surgery, 2021, 91, 279-286. | 1.1 | 0 |
| 175 | Choosing Donors Wisely. Reducing the Risk of Transfusion-Transmissible Viral Infection through Blood Donor Selection: The Australian Experience 2000â€“2006.. Blood, 2007, 110, 2910-2910. | 0.6 | 0 |
| 176 | The Australian Hemovigilance System. , 0, , 209-219. | | 0 |
| 177 | Large Population Dataset Linkage to Understand Evolving Practice in Red Cell and Platelet Transfusion and Clinical Outcomes in Patients with Myelodysplastic Syndromes (MDS): A 15-Year Study. Blood, 2021, 138, 3255-3255. | 0.6 | 0 |
| 178 | Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Blood, 2021, 138, 4757-4757. | 0.6 | 0 |
| 179 | The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. Blood, 2020, 136, 30-31. | 0.6 | 0 |
| 180 | MÄori and Pacific peoples with multiple myeloma in New Zealand are younger and have inferior survival compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 2022, , . | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Congenital asplenia study: clinical and laboratory characterisation of adults with congenital asplenia. Annals of Hematology, 2022, , 1. | 0.8 | 0 |
| 182 | Whole blood for trauma resuscitation?. Injury, 2022, 53, 1573-1575. | 0.7 | 0 |
| 183 | Reply to comment on: Massive transfusion experience, current practice and decision support: A survey of Australian and New Zealand Anaesthetists. Anaesthesia and Intensive Care, 2022, , 0310057X2110608. | 0.2 | 0 |